Mitochondria-Related Gene Model Suggests Associations with Colorectal Cancer Prognosis and Immune Cell Infiltration
Colorectal cancer prognosis examined through gene expression
A risk model built from the expression of mitochondria-related genes in patients with colorectal cancer showed potential for predicting prognosis. The researchers found significant differences in immune cell infiltration between high- and low-risk groups and reported that risk scores were also associated with clinicopathological characteristics and drug sensitivity. However, the provided abstract gives no predictive performance metrics, making it difficult to assess the model’s usefulness in clinical practice.
Published in Neoplasma, the study combined analyses of publicly available patient data with an ABCD3 overexpression experiment. Against the background of associations between mitochondrial dysfunction and colorectal cancer development and progression, the researchers examined whether expression data for related genes could serve as indicators for distinguishing patients by prognosis. The study does not establish a causal relationship in which mitochondrial dysfunction determines the rate of cancer progression.
A risk model built and validated with public data
The researchers analyzed gene expression data from patients with colorectal cancer in the TCGA and GEO databases and used several bioinformatics methods to build and validate a prognostic model based on mitochondria-related genes. They also analyzed the tumor microenvironment, immune cell infiltration, tumor mutational burden, and drug sensitivity.
The abstract describes the model as effective for predicting prognosis in patients with colorectal cancer. It reports significant differences in immune cell infiltration between the high- and low-risk groups, and strong associations between risk scores and clinicopathological characteristics, immune cell infiltration, and drug sensitivity. These findings suggest that risk groups defined by gene expression may also be related to the tumor’s immune environment.
The abstract does not specify which immune cells differed or in what direction, nor does it describe how sensitivity to particular drugs varied. Tumor mutational burden is mentioned as an analysis item, but no specific results are provided. An association with drug sensitivity cannot be interpreted directly as an ability to predict individual patients’ responses to anticancer treatment.
What the ABCD3 functional experiment shows
The researchers used CRISPR-dCas9 technology to overexpress ABCD3 and examined its role in cell proliferation and cell death using western blotting and flow cytometry. They proposed ABCD3 as a candidate biomarker for personalized treatment of colorectal cancer; the paper’s title also presents it as a potential therapeutic target.
However, the abstract does not report the direction or magnitude of changes in cell proliferation or cell death after ABCD3 overexpression. It therefore cannot be concluded that increasing ABCD3 expression suppresses cancer cell proliferation or induces cell death. Nor can the results be considered evidence that ABCD3-targeted treatment is effective in patients.
Validation still needed before clinical use
The provided abstract does not give the number of patients or their stage distribution, the genes included in the model or how its score was calculated, the definitions of the prognostic endpoints, the follow-up period, or predictive performance metrics. It is also difficult to determine how much the model improves prediction over existing clinical indicators, or whether the drug sensitivity analysis reflects actual treatment responses in patients.
This study presents a candidate model linking mitochondria-related gene expression with prognosis and the immune environment. Assessing its clinical applicability will require examining the model’s composition and validation methods, as well as its reproducibility in independent patient cohorts and the added predictive value it provides over existing indicators. Whether it can help guide anticancer drug selection or improve survival requires separate clinical validation.
Details of the study can be found in the provided bibliographic record and abstract of the Neoplasma paper.
Studies have shown that abnormal mitochondrial function is closely associated with the development and progression of colorectal cancer (CRC); however, prognostic models based on mitochondria-related genes are still lacking. We systematically analyzed the expression of mitochondrial-related genes in CRC patients and constructed and validated a mitochondrial gene risk prognostic model using various bioinformatics methods across the TCGA and GEO databases. We also investigated the effects of tumor microenvironment, immune cell infiltration, tumor mutation load, and drug sensitivity on patient prognosis. In addition, we overexpressed the ABCD3 gene using CRISPR-dCas9 technology and further explored the role of ABCD3 in cell proliferation and apoptosis by protein blotting and flow cytometry. The mitochondrial gene risk model was effective in predicting the prognosis of CRC patients, which showed that the high-risk group was significantly different from the low-risk group in terms of immune cell infiltration. Further analyses revealed a strong association between risk scores and clinicopathological features, immune infiltration, and drug sensitivity. We constructed a prognostic prediction model based on mitochondria-related genes and found that ABCD3 provides a novel biomarker for the individualized treatment of CRC.
The study’s practical value lies in analyzing mitochondria-related gene expression in relation not only to patient prognosis but also to immune cell infiltration. For researchers, it offers a starting point for exploring biological differences between risk groups and testing ABCD3 function in follow-up experiments. However, a marker associated with prognosis does not necessarily predict treatment response. Follow-up studies should establish the model’s composition and performance, its added predictive value over existing clinical indicators, and its reproducibility in independent patient cohorts. ABCD3’s functional effects when its expression is altered should also be evaluated separately from its potential as a therapeutic target. The provided abstract alone cannot support decisions on selecting a particular anticancer drug or establish the effectiveness of ABCD3-targeted treatment.